In the study, 135 subjects with mild knee osteoarthritis received either 250 mg (50 mg curcuminoids) or 500 mg (100 mg curcuminoids) of Curcuwin Ultra+ per day for 84 days.
OmniActive Health Technologies (Morristown, NJ) has announced the results of a clinical study expected to be published later this year. In the study, 135 subjects with mild knee osteoarthritis received either 250 mg (50 mg curcuminoids) or 500 mg (100 mg curcuminoids) of Curcuwin Ultra+ per day for 84 days. Both doses resulted in improvements in overall joint health comfort and mobility as early as five days, and persisted throughout the study.
“The results of this robust study demonstrated that a low dose of just 250 mg (50 mg curcuminoids) of Curcuwin Ultra+ may serve as a unique nutritional solution for managing issues related to knee joint comfort and mobility including cartilage health,” said Deshanie Rai, PhD, FACN, vice president, global scientific and regulatory affairs at OmniActive, in a press release. The ingredient was shown in a study published earlier this year to be 144 times more bioavailable than standard curcumin at a dose of 250 mg.1
Reference
U.S. Hemp Authority announces Adult Use Hemp Product Certification Program
April 15th 2024The U.S. Hemp Authority (USHA) has announced the launch of its Adult Use Hemp Product Certification Program in an effort to “reshape public policy around hemp, and to build confidence among retailers and consumers alike.”
Microalgae extract supports metabolic health and bone mass during diet and exercise routine
April 11th 2024The extract from Microphyt, called PhaeOptim, was shown to complement weight management strategies that include diet and exercise by support bone mass, aerobic capacity, resting heart rate, and blood lipid profiles.